Type of Intervention: Regulation
Sectors Involved: Health
Level of Jurisdiction: National
Lead People/Agency: Drugs Controller General of India; Ministry of Health and Family Welfare
Overview: Based on Phase II clinical trial results generated in COVID-19 patients, the Drugs Controller General of India (DCGI) gives nod for restricted emergency use to Itolizumab for moderate to severe COVID-19 patients.
Full details here: https://pib.gov.in/PressReleasePage.aspx?PRID=1637926
Type of Justification: Advice of INTERNAL government advisory committee or group, Scientific Evidence (e.g. academic paper, report)